The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

JOHANNESBURG (AP) — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between with US pharmaceutical giant Gilead ...

US antivirals specialist Gilead Sciences today announced a strategic partnership agreement with the Global Fund to Fight AIDS ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...